BrickBio has developed a bioconjugation platform that enables site-specific modification of proteins, facilitating precise protein engineering for research applications. This technology enhances the study of protein functions and interactions, providing researchers with improved tools for understanding complex biological processes.
Funding
$12.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current bioconjugation methods for creating antibody-drug conjugates (ADCs) and protein therapeutics often suffer from heterogeneity, instability, and imprecise control over the conjugation site, leading to suboptimal clinical outcomes and a high failure rate in therapeutic development. Traditional approaches lack the ability to efficiently incorporate synthetic amino acids at specific locations within a protein backbone, limiting the creation of optimized biologics.
Solution
BrickBio offers a bioconjugation platform, the ETRNAL (Evolved tRNA Localization) Platform, that enables site-specific incorporation of synthetic amino acids into proteins, facilitating the development of homogenous and stable antibody-drug conjugates (ADCs) and protein therapeutics. The platform leverages evolved tRNA molecules and mammalian expression systems to incorporate conjugation handles at novel, optimized sites within any protein backbone. This technology allows for precise customization of proteins, leading to safer and more efficacious therapeutics with an improved therapeutic window. BrickBio's approach addresses the limitations of existing conjugation technologies by providing stable conjugation sites that can shield undesired properties and enable unprecedented biophysical characteristics.
Target Audience
The primary customers are biotech and pharmaceutical companies involved in developing antibody-drug conjugates (ADCs) and protein therapeutics, as well as researchers in the field of protein engineering and bioconjugation.
Features
- Mammalian expression systems for efficient synthetic amino acid incorporation at any site within a protein backbone.
- ETRNAL Platform enables 10x more efficient machinery for synthetic amino acid incorporation and diverse chemistries.
- Site-Selection Panel Algorithm driven by empirical and literature data for optimal conjugation site prediction.
- Capability to create multi-payload conjugates with synergistic mechanisms of action.
- First-in-class stable CHO cell line for commercial scalability.
- Technology to shield ADC payloads and optimize their activity.